Abacavir/lamivudine and efavirenz — Competitive Intelligence Brief

Abacavir/lamivudine and efavirenz (Abacavir/lamivudine and efavirenz) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NRTI + NNRTI). Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy (NRTI + NNRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Abacavir/lamivudine and efavirenz (Abacavir/lamivudine and efavirenz) — GlaxoSmithKline. This combination of three antiretroviral drugs inhibits HIV replication by blocking reverse transcriptase and integrase enzymes, preventing the virus from copying its genetic material and integrating into host cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Abacavir/lamivudine and efavirenz TARGET	Abacavir/lamivudine and efavirenz	GlaxoSmithKline	marketed	Antiretroviral combination therapy (NRTI + NNRTI)	HIV reverse transcriptase
Raltegravir; Abacavir/Lamivudine	Raltegravir; Abacavir/Lamivudine	Central Institute of Epidemiology, Moscow, Russia	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase; HIV reverse transcriptase
Raltegravir and Abacavir/Lamivudine	Raltegravir and Abacavir/Lamivudine	Denver Infectious Disease Consultants, PLLC	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase, HIV reverse transcriptase
Raltegravir and truvada	Raltegravir and truvada	The University of Texas Health Science Center, Houston	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase; HIV reverse transcriptase
Cabotegravir LA + Rilpivirine LA	Cabotegravir LA + Rilpivirine LA	Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia	marketed	Antiretroviral combination (INSTI + NNRTI)	HIV integrase and HIV reverse transcriptase
Tenofovir disoproxil/emtricitabine/rilpivirine	Tenofovir disoproxil/emtricitabine/rilpivirine	Sheba Medical Center	marketed	Antiretroviral combination (NRTI + NNRTI)	HIV reverse transcriptase
tenofovir + abacavir + efavirenz	tenofovir + abacavir + efavirenz	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI + NNRTI)	HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NRTI + NNRTI) class)

1. GlaxoSmithKline · 2 drugs in this class
2. Clinical Trial Agency of HIV Study Group · 1 drug in this class
3. Hospital Clinic of Barcelona · 1 drug in this class
4. Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · 1 drug in this class
5. National Center for AIDS/STD Control and Prevention, China CDC · 1 drug in this class
6. Peking Union Medical College Hospital · 1 drug in this class
7. Sheba Medical Center · 1 drug in this class
8. Azienda Ospedaliera San Gerardo di Monza · 1 drug in this class
9. University of KwaZulu · 1 drug in this class